ӳ��ý

Cancer Program

The challenges in treating Embryonal Tumors with Multilayered Rosettes (ETMR) and other infant brain tumors.

Bandopadhayay P, Chi SN. The challenges in treating Embryonal Tumors with Multilayered Rosettes (ETMR) and other infant brain tumors. Neuro Oncol. 2021. doi:10.1093/neuonc/noab206

Telomerase as a therapeutic target in glioblastoma.

Aquilanti E, Kageler L, Wen PY, Meyerson M. Telomerase as a therapeutic target in glioblastoma. Neuro Oncol. 2021. doi:10.1093/neuonc/noab203

Molecular basis for substrate recruitment to the PRMT5 methylosome.

Mulvaney KM, Blomquist C, Acharya N, et al. Molecular basis for substrate recruitment to the PRMT5 methylosome. Mol Cell. 2021;81(17):3481-3495.e7. doi:10.1016/j.molcel.2021.07.019

60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.

Cieri N, Maurer K, Wu CJ. 60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy. Cancer Res. 2021;81(17):4373-4384. doi:10.1158/0008-5472.CAN-21-0301

Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer.

Singh H, Perez K, Wolpin BM, Aguirre AJ. Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. J Clin Oncol. 2021:JCO2101510. doi:10.1200/JCO.21.01510

Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy.

Miller PG, Sperling AS, Brea EJ, et al. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021;5(15):2982-2986. doi:10.1182/bloodadvances.2021004554

Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction.

McKinney DC, McMillan BJ, Ranaghan MJ, et al. Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction. J Med Chem. 2021. doi:10.1021/acs.jmedchem.1c00507

Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.

Pikman Y, Ocasio-Martinez N, Alexe G, et al. Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy. Leukemia. 2021. doi:10.1038/s41375-021-01361-8

Epigenetic scars of CD8 T cell exhaustion persist after cure of chronic infection in humans.

Yates KB, Tonnerre P, Martin GE, et al. Epigenetic scars of CD8 T cell exhaustion persist after cure of chronic infection in humans. Nat Immunol. 2021;22(8):1020-1029. doi:10.1038/s41590-021-00979-1

Phenotype, specificity and avidity of antitumour CD8 T cells in melanoma.

Oliveira G, Stromhaug K, Klaeger S, et al. Phenotype, specificity and avidity of antitumour CD8 T cells in melanoma. Nature. 2021;596(7870):119-125. doi:10.1038/s41586-021-03704-y